Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

#RemoteDetailing

Bristol-Myers Squibb (BMS) building

BMS claims a win in mid-stage NASH trial

Its new liver disease therapy reduces fatty deposits and improves blood lipid profiles

EU flag

CHMP backs two rare disease therapies at April meeting

Biogen's Spinraza and BioMarin's Brineura near EU approval

- PMLiVE

ThermiGen appoints Vladimir Paul-Blanc as president

He will also serve as the Almirall-owned firm's general manager

- PMLiVE

Porterhouse Medical promotes Richard Oakham

He takes up creative services manager role

Brexit: the facts (and the alternative facts)

How Brexit affects pharma

- PMLiVE

UniQure pulls first EU gene therapy

Decision made due to lack of demand

How will capitated budgets affect NHS spending?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess the implications of a single budget covering all the physical, mental and social care needs of patients in an STP

Wilmington Healthcare

- PMLiVE

Amgen sues Sanofi and Regeneron over eczema drug

Alleges patent infringement and seeks financial reparations

- PMLiVE

Lucid Group Achieve UK’s Highest Award for Business Success

Lucid Group have been chosen to receive a Queen’s Award for Enterprise in International Trade. This award is widely regarded as the UK’s highest accolade for business success and they...

Lucid Group Communications Limited

- PMLiVE

Brexit: Implications for the pharma industry

From patents to the EMA, data protection to clinical trials, there's a lot that should be a concern

- PMLiVE

AbbVie’s PARP inhibitor veliparib fails to deliver

Phase III trials show no increase in clinical benefit

- PMLiVE

Verily’s Baseline health project seeks 10,000 volunteers

Four-year study to produce a molecular snapshot

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links